Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
30.77
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
November 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 15, 2021
Gainers Kezar Life Sciences (NASDAQ:KZR) s...
Via
Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
November 09, 2021
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:
Via
Benzinga
Cramer Likes DraftKings, Skyworks, And These Automakers
October 07, 2021
On CNBC's "Mad Money Lightning Rou...
Via
Benzinga
Better Pharmaceutical Stock: Apellis or Novartis?
September 15, 2021
The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments.
Via
Talk Markets
Raymond James Upgraded This Biopharma Stock And Sees 44% Upside
September 13, 2021
Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ:
Via
Benzinga
60 Biggest Movers From Friday
September 13, 2021
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in...
Via
Benzinga
Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher
September 10, 2021
Toward the end of trading Friday, the Dow traded down 0.31% to 34,772.74 while the NASDAQ fell 0.27% to 15,207.42. The S&P also fell, dropping 0.28% to 4,480.86. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What 11 Analyst Ratings Have To Say About Apellis Pharmaceuticals
September 10, 2021
Over the past 3 months, 11 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:
Via
Benzinga
8 Health Care Stocks With Unusual Options Alerts In Today's Session
September 10, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today
September 10, 2021
Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results.
Via
InvestorPlace
Dow Eyes Fifth-Straight Skid, Another Weekly Drop
September 10, 2021
The Dow Jones Industrial Index is giving up its earlier gains, last seen down 149 points, as investors fail to shake off the economic uncertainty that's blanketed the holiday-shortened week.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Apellis Pharmaceutical Shares Are Plunging Today
September 10, 2021
Apellis Pharmaceuticals Inc (NASDAQ: APLS) is trading lower Friday after the company announced its Phase 3 DERBY study in geographic atrophy did not meet the primary...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 10, 2021
Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC bio's stock is trading at a volume of 120.3 million...
Via
Benzinga
Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge
September 10, 2021
Midway through trading Friday, the Dow traded down 0.40% to 34,739.37 while the NASDAQ fell 0.06% to 15,238.92. The S&P also fell, dropping 0.21% to 4,483.84. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
41 Stocks Moving In Friday's Mid-Day Session
September 10, 2021
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic...
Via
Benzinga
Here's Why Iveric Bio Stock Is Rocketing Higher Today
September 10, 2021
Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program.
Via
The Motley Fool
ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio
September 10, 2021
IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today.
Via
InvestorPlace
Here's Why Apellis Pharmaceuticals Is Getting Hammered Today
September 10, 2021
Conflicting clinical trial results for the company's lead candidate are to blame.
Via
The Motley Fool
Why IVERIC Bio Shares Are Soaring Today
September 10, 2021
IVERIC Bio Inc (NASDAQ: ISEE) is trading significantly higher Friday after Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported results from its Phase 3 DERBY and OAKS studies...
Via
Benzinga
Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views
September 10, 2021
Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also rose, gaining 0.03% to 4,494.53. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Apellis Loses A Third Of Its Value; Are Its Mixed Results Enough To Win FDA OK?
September 10, 2021
Apellis Pharmaceuticals reported mixed results for an eye-disease treatment, leading APLS stock to crash on Friday.
Via
Investor's Business Daily
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
September 10, 2021
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Friday
September 10, 2021
Wells Fargo lowered the price target on General Motors Company (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 10, 2021
Gainers IVERIC bio (NASDAQ:ISEE) stock increased by 65.36% to $14.37 during Friday's pre-market session. The company's market cap stands at $1.4 billion. T2...
Via
Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
September 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
20 Stocks Moving in Friday's Pre-Market Session
September 10, 2021
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4). T2...
Via
Benzinga
Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line
September 10, 2021
Apellis Pharmaceuticals Inc's (NASDAQ: APLS) pegcetacoplan posted mixed results in two Phase 3 trials in 1,258 geographic atrophy (GA). Despite the mixed...
Via
Benzinga
Exposures
Product Safety
Where Apellis Pharmaceuticals Stands With Analysts
August 19, 2021
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.